BofA warns Fed risks policy mistake with early rate cuts
Investing.com -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) stock rose 15% after the company announced it received U.S. patent approval for its ART500 core technology, a low flow rates extracorporeal oxygenation system.
The patent, which includes 16 claims found to be novel, provides protection for the underlying technology of the ART500 system until at least 2043. The device is designed to deliver extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency.
According to the company, this innovation targets patients requiring respiratory support who may not be sick enough for traditional high-flow ECMO systems, potentially expanding Inspira’s addressable market.
Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, emphasized the patent’s significance: "This patent has profound business implications for Inspira and for our ability to dominate a market with a potential size of $20 billion. We are creating a new therapeutic category for conscious, spontaneously breathing patients."
The company is pursuing additional patents in major jurisdictions worldwide to expand its intellectual property coverage. Inspira Technologies describes itself as a pioneer in innovative life-support and diagnostic technologies.
The ART500 system complements the company’s ART100 system, which Inspira reports is already generating commercial momentum. The patent approval strengthens Inspira’s intellectual property portfolio in the field of advanced extracorporeal life support.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.